[The selection of a drug in a defined therapeutic class: the case of the HMG-CoA reductase inhibitors]. / Sélection d'un medicament dans une classe thérapeutique donnée: l'exemple des "inhibiteurs de l'HMG-CoA reductase"

ABSTRACT

The HMG-CoA reductase inhibitors have similar therapeutic targets and indications. However, their potential pharmacokinetic drug-drug interaction profile may play a significant role in their safety profile in polymedicated and polymorbid patients and can serve as a selection criterion. If their utility is clearly demonstrated in selected conditions, their safety profile remains of concern. Beside dose-related hepatic and muscular injury, other rare and important adverse drug reactions have been reported after prolonged administration such as polyneuropathy, fibrotic interstitial pulmonary disease and lupus-like syndrome. Teratogenicity has also been associated with statin therapy.